CA1241016A - Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives - Google Patents
Method for the production of nuclear substituted cinnamoylanthranilic acid derivativesInfo
- Publication number
- CA1241016A CA1241016A CA000478780A CA478780A CA1241016A CA 1241016 A CA1241016 A CA 1241016A CA 000478780 A CA000478780 A CA 000478780A CA 478780 A CA478780 A CA 478780A CA 1241016 A CA1241016 A CA 1241016A
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- acid
- accordance
- cyclic amine
- nuclear substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- GMEKUFJCKPYDAH-UHFFFAOYSA-N 2-(3-phenylprop-2-enoylamino)benzoic acid Chemical class OC(=O)C1=CC=CC=C1NC(=O)C=CC1=CC=CC=C1 GMEKUFJCKPYDAH-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- -1 cyclic amine Chemical class 0.000 claims abstract description 28
- LZEMYXZYMHWMMN-UHFFFAOYSA-N 2-(phenylcarbamoyl)propanedioic acid Chemical compound OC(=O)C(C(O)=O)C(=O)NC1=CC=CC=C1 LZEMYXZYMHWMMN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 150000003935 benzaldehydes Chemical class 0.000 claims abstract description 9
- 239000002244 precipitate Substances 0.000 claims abstract description 7
- 239000000376 reactant Substances 0.000 claims abstract description 7
- 239000012445 acidic reagent Substances 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 14
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical group COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- FSKJPXSYWQUVGO-UHFFFAOYSA-N 2-[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoylamino]benzoic acid Chemical group C1=C(O)C(OC)=CC(C=CC(=O)NC=2C(=CC=CC=2)C(O)=O)=C1 FSKJPXSYWQUVGO-UHFFFAOYSA-N 0.000 claims description 5
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- AVHHJLURQYHHDR-UHFFFAOYSA-N 2-[3-(3-hydroxy-4-methoxyphenyl)prop-2-enoylamino]benzoic acid Chemical group C1=C(O)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O AVHHJLURQYHHDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- MWOOGOJBHIARFG-OUBTZVSYSA-N 4-hydroxy-3-methoxybenzaldehyde Chemical group [13CH3]OC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-OUBTZVSYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- JJVNINGBHGBWJH-UHFFFAOYSA-N ortho-vanillin Chemical compound COC1=CC=CC(C=O)=C1O JJVNINGBHGBWJH-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- NZHGWWWHIYHZNX-UHFFFAOYSA-N 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-UHFFFAOYSA-N 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- GRIWJVSWLJHHEM-UHFFFAOYSA-N 3-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=C(O)C=CC=C1C=O GRIWJVSWLJHHEM-UHFFFAOYSA-N 0.000 description 1
- HXLDCOVUIPCODC-UHFFFAOYSA-N 3-hydroxy-2-methoxybenzaldehyde;3-hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1O.COC1=C(O)C=CC=C1C=O HXLDCOVUIPCODC-UHFFFAOYSA-N 0.000 description 1
- PMCWOGATSZLJKS-UHFFFAOYSA-N 3-hydroxy-4-propoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1O PMCWOGATSZLJKS-UHFFFAOYSA-N 0.000 description 1
- JUUPYFMXANQBND-UHFFFAOYSA-N 3-phenylprop-2-enoyl 2-aminobenzoate Chemical class NC1=CC=CC=C1C(=O)OC(=O)C=CC1=CC=CC=C1 JUUPYFMXANQBND-UHFFFAOYSA-N 0.000 description 1
- QKMNBOPIPCIBFG-UHFFFAOYSA-N 4-[3-(2-carboxyanilino)-3-oxoprop-1-enyl]-2-methoxyphenolate;pyrrolidin-1-ium Chemical compound C1CC[NH2+]C1.C1=C([O-])C(OC)=CC(C=CC(=O)NC=2C(=CC=CC=2)C(O)=O)=C1 QKMNBOPIPCIBFG-UHFFFAOYSA-N 0.000 description 1
- CBKYEFKMNADVGO-UHFFFAOYSA-N 4-hydroxy-3-propoxybenzaldehyde Chemical compound CCCOC1=CC(C=O)=CC=C1O CBKYEFKMNADVGO-UHFFFAOYSA-N 0.000 description 1
- ZBURODYGHXGIML-UHFFFAOYSA-N 5-[3-(2-carboxyanilino)-3-oxoprop-1-enyl]-2-methoxyphenolate;pyrrolidin-1-ium Chemical compound C1CC[NH2+]C1.C1=C([O-])C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O ZBURODYGHXGIML-UHFFFAOYSA-N 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Abstract:
The invention provides an improved method for producing cinnamoylanthranilic acid compounds having hydroxy and alkoxy substituents. The method involves reacting a nuclear substituted benzaldehyde derivative with a 2-carboxy malonanilic acid and a cyclic amine.
The reaction is carried out in an inert solvent medium and the cyclic amine is employed in a molar ratio of about 2-10 moles per mole of substituted benzaldehyde derivative reactant or 2-carboxy malonanilic acid re-actant. This produces a crystalline precipitate of a cyclic amine salt which can be separated and then treated with an acid reagent to yield the desired compound.
The invention provides an improved method for producing cinnamoylanthranilic acid compounds having hydroxy and alkoxy substituents. The method involves reacting a nuclear substituted benzaldehyde derivative with a 2-carboxy malonanilic acid and a cyclic amine.
The reaction is carried out in an inert solvent medium and the cyclic amine is employed in a molar ratio of about 2-10 moles per mole of substituted benzaldehyde derivative reactant or 2-carboxy malonanilic acid re-actant. This produces a crystalline precipitate of a cyclic amine salt which can be separated and then treated with an acid reagent to yield the desired compound.
Description
o~6 A method for the production of nuclear substituted cinnamoYlanthranilic acid derivatives This invention relates to a novel method for the production of nuclear substituted cinnamoylanthranilic acid derivatives. More particularly, this invention relates to an improved method for the production of nuclear di-substituted cinnamoylanthranilic acid deri-vatives which possess antiallergic properties and thus are useful for treatment of diseases such as asthma, hay fever, atopic dermatitis and urticaria.
Nuclear substituted cinnamoylanthranilic acid derivatives such as N-(3,4-dimethoxycinnamoyl)anthranilic acid are known to exhibit strong antiallergic properties and to be useful for treatment of asthma, hay fever, atopic dermatitis and urticaria, as reported in U.S.
Patent Number 4,070,484; Allergy, 34, 213-219, (1979);
and Igaku no Ayumi, 106, No. 8 576-585 (1978).
~,Z4~0~6 Several methods for producing said derivatives have ~een also disclosed in published Japanese patent application Nos. 7359/73, 42273/74, 42465/74, 43673/74, 43678/74, 158554/75, 158555/75, 158556/75, 139368/76, 38555/80, 38556/80 and 8858/81, and in U.S. Patent No. 3,940,422. O~ the methods disclosed in the above patent re~erences, the process described in published Japanese patent application No. 8858/81 can be operated with ease and efficiency, and thus this process has advantage for production on an industrial scale. The Japanese patent application No. 8858/81 invention is illustrated by the following preferred process embodiment.
A nuclear unsubstituted or substituted benzaldehyde derivative i5 heated with a 2-carboxymalonanilic acid derivative at 80-100C for several hours in a solvent medium such as pyridine, benzene, toluene or xylene tlo-2o times by weight the amount of the benzaldehyde derivative or the
Nuclear substituted cinnamoylanthranilic acid derivatives such as N-(3,4-dimethoxycinnamoyl)anthranilic acid are known to exhibit strong antiallergic properties and to be useful for treatment of asthma, hay fever, atopic dermatitis and urticaria, as reported in U.S.
Patent Number 4,070,484; Allergy, 34, 213-219, (1979);
and Igaku no Ayumi, 106, No. 8 576-585 (1978).
~,Z4~0~6 Several methods for producing said derivatives have ~een also disclosed in published Japanese patent application Nos. 7359/73, 42273/74, 42465/74, 43673/74, 43678/74, 158554/75, 158555/75, 158556/75, 139368/76, 38555/80, 38556/80 and 8858/81, and in U.S. Patent No. 3,940,422. O~ the methods disclosed in the above patent re~erences, the process described in published Japanese patent application No. 8858/81 can be operated with ease and efficiency, and thus this process has advantage for production on an industrial scale. The Japanese patent application No. 8858/81 invention is illustrated by the following preferred process embodiment.
A nuclear unsubstituted or substituted benzaldehyde derivative i5 heated with a 2-carboxymalonanilic acid derivative at 80-100C for several hours in a solvent medium such as pyridine, benzene, toluene or xylene tlo-2o times by weight the amount of the benzaldehyde derivative or the
2-carboxymalonanilic acid derivative) in the presence of a catalytic amount of a basic compound such as piperidine. The resultant reaction mixture is evaporated and the residue is dissolved in a small amount of an alcohol. The alcoholic solution is poured into ice-water, then hydrochloric acid is added to make the aqueous medium acidic, and the crystalline precipitate which forms is collected by filtration and recrystallized from a suitable organic solvent to yield the desired product.
l 12410~
` Since the desired product in the above described procedure is obtained as a precipitate from an aqueous acidic solution of the evaporated reaction mixture by acidification with a mineral acid, unreacted materials and byproducts which are insoluble in an aqueous acidic solution J are also precipitated, and these components are difficult to ~j remove by recrystallization and thus are contained in the desired product. Hence, the desired product purified by !! recrystallization always contains such impurities and is not I applicable for medicinal purposes without an extensive recrystallization procedure, with a concomitant decrease in product yield.
Accordingly, it is an object of this invention to l provide a process for producing anthranilic acid derivatives 1 which is superior to prior art methods such as that described l in Japanese patent application No. 8858/81.
J It is another object of this invention to provide an improved method for producing nuclear di-substituted cinnamoyl-! anthranilic acid derivatives with a high purity and yield, li which derivatives possess antiallergic properties and thus ¦¦ are useful for treatment of asthma, hay fever, atopic dermatitis i and urticaria.
! Other objects and advantages of this invention willbecome apparent from the accompanying description and examples.
i' 1241016 "
i. .' DESCRIPTION OF THE INVENTION
This invention provides an improved method for the production of nuclear substituted cinnamoylanthranilic acid ' derivatives corresponding to the formula:
i COOH
1 2~CH=CHCONH ~ (I) Ii ' jj where Rl is hydroxyl and R2 is an alkoxyl substituent containing .
j about 1-3 carbon atoms. The said derivatives possess ,1 antiallergic properties, and are useful for treatment of ! diseases caused by allergies, such as asthma, hay fever, I atopic dermatitis and urticaria.
Thus, one or more objects of the present invention are accomplished by the provision of a process which comprises i reacting a nuclear di-substituted benzaldehyde corresponding to the formula:
1, ?l i ? ~ CHO
1I Rl ~ (II) .j ll ~24~0~6 where Rl and R2 are substituents as previously defined, in ~¦ an inert organic solvent with 2-carboxymalonanilic acid corresponding to the formula:
il'' .
i 11 ~ NHCOCH2COOH (III) I.j ~ COOH
~I !
~ and a cyclic amine corresponding to the formula:
(CH2)2 ~
HN X (IV) (CH2)n ~
.1 .
Il where X is a methylene group or an oxygen atom, n is 1 or 2 ¦¦ with the proviso that n is 2 when X is an oxygen atom, and s~id l cyclic amine is employed in a molar ratio of about 2-10 moles ¦ per mole of nuclear substituted benzaldehyde derivative of l formul.(II) or the 2-carboxymalonanilic acid of Formula(III) Il Il .
I I _ 5 I ~24~
I
i! above, to produce a crystalline precipitate of an intermediate ¦¦ compound corresponding to the formula:
. . ,i ' 1,, .
I ' COO~
Rl =0_ CH=C HCoN H ~3 '¦ ~ (CH2) i H (CH2) ~
I! where Rl, R2, X and n are as previously defined; and treating '¦ the said compound ~V) under acidic conditions to yield a jl product corresponding to formula(I) above.
-In the present invention process a specific type of cyclic amine compound is utilized in a molar ratio of j 2-10 moles per mole of the starting material of formula(II) ¦ or (III).above. 8y employing a molar excess of the cyclic ¦~ amine over the benzaldehyde(II) or 2-carboxymalonanilic acid~III) compounds in an inert organic solvent as a reaction medium, the 1~ .
Il i2~1016 intèrmediate of formula(V), i.e., the salt of nuclear substituted ! cinnamoylanthranilic acid derivative and cyclic amine, precipitates as crystals in high yield and purity from the ~ reaction mixture as the reaction proceeds, and thereafter is ~ readily recovered from the reaction mixture. The crystalline compound(V) is substantially free of unreacted materials and 'j byproducts and can be converted easily into the desired l~ free acid product in a high purity form by treatment with an ~ll acidic reagent such as a mineral acid.
ll As demonstrated in the Examples, the optimal yield i! of high purity crystalline salt intermediate is achieved when l! the molar ratio of cyclic amlne to benzaldehyde(II) or i 2-carboxymalonanilic acid~III) is about 3~
l ~hus, by the practice of the present invention process ~ the problems associated with the procedure disclosed in ¦ Japanese patent application No. 8858/81 are eliminated, and il nuclear substituted cinnamoylanthranilic acid derivatives ¦ are prepared efficiently in high yield and purity.
~1 Illustrative of inert organic solvents suitable in 0 il the invention process (i.e., solvents with solubility properties which promote crystallization of the intermediate(V) Ij as the reaction proceeds) are benzehe, toluene, xylene, ethyl ¦¦ acetate and chloroform. Preferred inert organic solvents are il aromatic hydrocarbons such as benzene and toluene. The solvent 5 ~1 is employed in a volume which typically will vary between about 1-30 milliliters per gram of benzaldehyde and 2-carboxymalonanilic acid reactants.
I
1! - 7 241~
The cyclic amine component employed in the invention '~ process possesses a catalytic property for condensing a ¦¦ nuclear di-substituted benzaldehyde derivative and Il 2-carboxymalonanilic acid, and possesses properties which 1~ enhance the formation of insoluble cyclic amine salt of ,¦ cinnamoylanthranilic acid derivativë in an inert solvent ,j medium. Illustrative of the invention cyclic amines are pyrrolidine, piperidine and morpholine. Piperidine is an ¦ exceptional cyclic amine for purposes of the present invention lo 31 process.
!l Acid reagents suitable for the conversion of the ! intermediate(V) compound above into the desired compound(I) Ij include inorganic acids such as hydrochloric acid, sulfuric ! I acid, and the like, and organic acids such as acetic acid or ! p-toluenesulfonic acid. The use of a mineral acid such as ¦¦ hydrochloric acid is preferred.
The nuclear di-substituted benzaldehyde derivatives corresponding to formula(II) which are employed as a starting I¦ material are known compounds, and methods of synthesis are 1I described in the chemical literature. Examples of said aldehydes include 2-hydroxy-3-methoxybenzaldehyde; 3-hydroxy-2-methoxy-benzaldehyde; 3-hydroxy-4-methoxybenzaldehyde;4-hydroxy-3-methoxybenzaldehyde; 3-hydroxy-4-propoxybenzaldehyde:
l 4-hydroxy-3-propoxybenzaldehyde; and the like.
25 ¦ 2-Carboxymalonanilic acid used as a starting material is also a known compound, and can be prepared according to the method described in ~apanese application No. 43673/74.
l - 8 -il. . .
i~
Z410~6 ¦¦ . Since dehydration and decarboxylation reactions occur simultaneously with the formation of the intermediate compound corresponding to formula(V) above, in a preferred Il process embodiment the reaction is conducted with continuous ,I removal of water formed during the reaction course.
As a general procedure, a mixture of a benzaldehyde !! derivative corresponding to formula(II), 2-carboxymalonanilic , acid, and 2-10 moles of cyclic amine corresponding to formula(IV) l (e.g., piperidine) per mole of the benzaldehyde derivative(II) l or 2-carboxymalonanilic acid(III) is dissolved in an inert organic solvent (e.g., benzene or toluene) in a proportion l of about 1-3 liters of solvent per mole of benzaldehyde ¦¦ derivative, and then the resultant reaction solution is ¦¦ heated under reflux for a period of about 3-5 hours with 15 1l continuous removal of water as it is formed during the reaction.
ij After cooling, the precipitated crystalline salt ~! intermediate is recovered by filtration and dissolved with Il heating in water. The resultant aqueous solution is added , dropwise to a dilute mineral acid solution. The crystalline ¦¦ product which precipitates is collected by conventional means !¦ such as filtration, and optionally, recrystallized from an Il organic solvent to provide the desired product corresponding to formula(I~.
1l1 .''1 I! 9 `I ~24~016 ¦ . It is an advantage of the invention process that the cyclic amine that is utilized can be recovered from the filtrate i and recycled in the process.
Il The following Examples are further illustrative of the !¦ present invention. The specific ingredients and processing I parameters are presented as being typical, and various " modifications can be derived in view of the foregoing disclosure j' within the scope of the invention.
.
,' .
. I
,`' 1,~
I I .
i `I ~Z~0~6 'i I, EXAMPLE I
This Example illustrates the advantages of preparing j nuclear substituted cinnamoylanthranilic acid derivatives ¦j with a molar excess of cyclic amine in accordance with the ~¦ present invention process.
A.
" A solution of 2.54 g of 4-hydroxy-3-methoxy-benzaldel~yde 3.8 g of 2-carboxymalonanilic acid, and I¦ 4.29 g of piperidine in 17 ml of benzene is heated for il 3 hours under reflux with removal of water of reaction. After ¦¦ completion of the reaction, the reaction mixture is cooled and the precipitated cry,stals are collected by filtration and ¦ dried to obtain 6.34 g of piperidinium N-(4-hydroxy-3-ll methoxycinnamoyl)anthranilate, m.p. 188-189C.
5 ¦ The compound structure is confirmed by elemental analysis, and by IR and NMR spectroscopy.
Il The molar ratio of'piperidine to 4 hydroxy-3-j, methoxybenzaldehyde in the above preparation is 3:1. The ~! same procedure is employed with 3-hydroxy-4-methoxybenzaldehyde !I to synthesize piperidinium N-(3-hydroxy-4-methoxycinnamoyl)-,1 anthranilate, m.p. 197-203C.
I; The same procedure is employed with different molar il ratios of piperidine to 4-hydroxy-3-methoxybenzaldehyde and ¦l 3-hydroxy-4-methoxybenzaldehyde, respectively.
'I
1' .4~1 0~6 ' The r~sults as summarized in Table I demonstrate the superiority of the present invention process for the production of a high yield of crystalline nuclear substituted Il cinnamoylanthranilate salt intermediate. Examples II and IV
'l illustrate the conversion of the crystalline piperidinium salts to the desired N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid and N-(3-hydroxy-4-methoxycinnamoyl)anthranilic acid products.
, I .
I~ B.
il In a manner similar to that described in IA above, ¦¦ comparative runs (Table II) are conducted with different molar ¦¦ ratios of morpholine to 4-hydroxy-3-methoxybenzaldehyde and ! 3-hydroxy-4-methoxybenzaldehyde, respectively. The crystalline salt intermediates are morpholinium N-(4-hydroxy-3-methoxy-l cinnamoyl)anthranilate (m.p. 183-185C) and morpholinium i N-(3-hydroxy-4-methoxycinnamoyl)anthranilate (m.p. 133-137C, 1I with decomposition).
Il Examples III and V illustrate the conversion of the I¦ crystalline morpholinium salts to N-(4-hydroxy-3-methoxy-¦¦ cinnamoyl)anthranilic acid and N-(3-hydroxy-4-methoxy-I cinnamoyl)anthranilic acid products of the invention. I
I
, 11 , !l 1~ , Il . .
j - 12 -li ~z~o~ ;
! .
.1 .. ` c.
; In a manner similar to that described in IA above, comparative runs (Table III) are conducted with different molar l¦ ratios of pyrrolidine to 4-hydroxy-3-metho~ybenzaldehyde and ll 3-hydroxy-4-methoxybenzaldehyde, respectively. The crystalline salt intermediates are pyrrolidinium N-(4-hydroxy-3-methoxy-cinnamoyl)anthranilate (m.p. 181-186C) and pyrrolidinium N-(3-hydroxy-4-methoxycinnamoyl)anthranilate (m.p. 175-179C).
~ Examples III and V illustrate the conversion of the ¦! crystalline pyrrolidinium salts to the free acid products of i¦ the invention.
i Similar results are obtained if the benzaldehyde reactant in all of the above described procedures i8 l 3-hydroxy-2-methoxybenzaldehyde or 2-hydroxy-3-methoxy-¦ benzaldehyde.
i jl :
~I .
1. , il `.
, i', ., ~
124101~, il __ ~ ~ ~
i j ~ N ~ , ~ ~)i OG ~r ~ N ~ ~
Q' ~ Ci ~ p~ O N; ~ ~ ~r ' ~D 'i U`i 1-- 11~ N If7 N
~: O ~ "
N o ~ U ~ D .
¦ ¦v ~ s ~ G
,, ~ ~ O O )fi ~ ~ ~
~i ~ ) Qt, ~ ~ ~
i x ~ ~ ~ oo o ~ N
~~ ~ u~
~ ~ V V . .. , il . ,~ ~, ~., ~_ ~ ~_ ~_ 9j~ , ~ Gi O N 1~ O
¢ ~ ~ ~i ~ OCi ~ N ~ t~ i 1` O 11~ ll~i 1~
~ ! Qi ~ O i~ S~ O ~ ~ ci N ~D O 11~ N
¦ ~i 0 Lo' ~C N ~
~ N O ~ ~ ~,~i ~ ~
lll ~ )=\ Ci ~ ~ ., ...... .. ~P d~ dP ~P oP dP ;
,i ,~x ~ ~ ~ ~ i t` Ni, I`
i l ~ ~i s~? ~
~ l x~ ~ ~ ~ ~
~i ~ ~i ?i ~ ~ a~ r, ~i No I' . ~ . "~
` !
~'i / Q' C / E ~ o o o o o ., / ~'i ,, / ~ C~
?? / z , i /
? _ `lZ41~
ll a) ~ ~ ~ ~ _.
~ ~ Ul ~ ~ O~ O ~D o O N ~ ~ ~ ~ a~ ~
., ~ ~ ~ O h Q~ O ~D ~ o ~ ~ ~ N
;~ ' 1~1 ~1 ~ O
,1 . ~ O O ~ Q, ~
. 3 X P: ~ ~ ~3 .
~i l ~ O
.,1 ~ ~
' 'I ~ ----- ., a ~1 ~ ~ O~ r oo o~ o I ¦ H ~ ~ 0~ ,_~ ~ ~1 er CO 1`
I I ~ ~ O ~ ~ ~ =~ O 0 ~
! l X /~\ ~g V ~ d~ dP dP dP d~ dP ;
, . E 0~/ V ~ ~ ~ ~ ~
. ~ h O 3 ~
ll ~ ~o~ ~ ~ ~
s . ~ ~ ~ ~
, I er ~ .~ h ~ ~r u7 a~ o j~
1~ . ~ In.
ll ... ''/ ._ _ _ __ _ l i.1 ~ / ~ ~ o o o o o .I j ~ / o ll / _ . __ __ k ~ ~ _ .- I
~. . I
__ ~ 016 .
I ~ ~ o ~ In o ~ J~ U) ~ ~i ~
!' ~ ~ o ~ ~ z~
. ~ . ~1 O ~ ~1 i! ~ ~ o~
! 1. o , I ~ ~ ~ 1~ h ~ 3oo ~, O O ~ X ~.
X ~ ~ o O ~ .~ ~ ~ ~
~o~-~ ~ ~ ~ ~ ~ O
j ~ ~ ~ o 'I ~ ~ . ~
;j ! I __ . I , ~, X~
! ~ ~ ~
~ . a) 3 ~ o ~ o ~D
I ~ It b~ 5 ,~ trt ~t o H ~ ~ O ~1 ~ _~ ~ cn a~ 1` 1`
i H 0~ ,~
i ~1 N ~ ~1 ~r ~ N
, m ~ 5: ~ ~ u ,~, ~D
Il ~ ~ U ~ ~t 9~ ~g i j Q ~ ~0 ~ -~ .. .. .. dP d d~ d~ dP ~P ? `
X ~ ~1 ut ~ t ~ ~ ~ u 1 ~ ~ ~.~2 ~ ~
~ ~ ~ ~ Qtl ' ~ o b' ~ ~
,~ s~ ~n ~ ~ ~ ~ ~' 1 ~ ~o~ ~ ~
I ! ~ rl ut r~
1 ~ ~2 u~
~l /
i ~ / a) ! ~ ~ ~ ~ o o o o o ~
; ~ /
! / ~ ~) Il / ~:
/
, C
I1 ~24~016 j' ~ EXAMPLE II
',l A 10 g quantity of piperidinium N-l4-hydroxy-3-methoxy-cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of Il water and 60 ml of methyl alcohol with heating, and the ~I resultant solution is added dropwise to 85 ml of diluted ~, hydrochloric acid (5 ml of conc. hydrochloric acid and ~0 ml of water) with stirring. The precipitated crystals which form are collected by filtration, washed with water and then dried at ,j 90-100C under r~duced pressure for 3 hours to yield ¦I N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid (98.5% yield), ¦i m.p. 230-233C. The compound structure is confirmed by jl elemental analysis, and by IR and NMR spectroscopy.
~1 , EXAMPLE III
~ A 10 g quantity of morpholinium N-(4-hydroxy-3-methoxy-I cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of ! water and 60 ml of methyl alcohol with heating, and the "
resultant solution is added dropwise to 85 ml of diluted hydrochloric acid t5 ml of conc. hydrochloric acid and 80 ml of ~, water) with stirring. The precipitated crystals which form are i~ collected by filtration, washed with water and then dried at 'i 90-100C under reduced pressure for 3 hours to yield Ij N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid (82.5~ yield).
il The compound is confirmed as identical to that obtained in I, EXAMPLE II.
!~ Similar results are obtained with pyrrolidinium ~j N-(4-hydroxy-3-methoxycinnamoyl)anthranilate.
!
I' . .
, - 14 -jl 124101~
. XAMPLE IV
A 10 g 4uantity of piperidlnium N-(3-hydroxy-4-methoxy-! cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of l water and 80 ml of methyl alcohol with heating, and the resultant ~jgolution is added dropwise to 85 ml of diluted hydrochloric acid ,l(5 ml of conc. hydrochloric acid and 80 ml of water) with ~ stirring. The precipitated crystals which form are collected ,',by filtration, washed with water and then dried at 90-100C
,lunder reduced pressure for 3 hours to yield N-(3-hydroxy-4-I¦methoxycinnamoyl)anthranilic acid (97.0% yield), m.p. 219-222C.
¦I The compound structure is confirmed by elemental analysis, and ¦~ by IR and NMR spectroscopy.
11 , I ~ EXAMPLE V
' A 10 g quantity of morpholinium N-(3-hydroxy-4-methoxy-l cinnamoy)anthranilate is dissolved in a mixture of 80 ml of ~ water and 60 ml of methyl alcohol with heating, and the resultant ;
jj solution is added dropwise to 85 ml of diluted hydrochloric acid j (5 mlof conc. hydrochloric acid and 80 ml of water) with stirring-, j~ The precipitated crystals which form are collected by filtration, 'I washed with water and then dried at 90-100C under reduced pressure for 3 hours to yield N-t3-hydroxy-4-methoxycinnamoyl)-,l anthranilic acid (74.0% yield). The compound is confirmed as identical to that obtained in EX~IPLE IV.
I¦ Similar results are obtained with pyrrolidinium 1¦ N- (3-hydroxy-4-metlloxycinnamoyl) anthr\nilate.
Il - 15-il .
l 12410~
` Since the desired product in the above described procedure is obtained as a precipitate from an aqueous acidic solution of the evaporated reaction mixture by acidification with a mineral acid, unreacted materials and byproducts which are insoluble in an aqueous acidic solution J are also precipitated, and these components are difficult to ~j remove by recrystallization and thus are contained in the desired product. Hence, the desired product purified by !! recrystallization always contains such impurities and is not I applicable for medicinal purposes without an extensive recrystallization procedure, with a concomitant decrease in product yield.
Accordingly, it is an object of this invention to l provide a process for producing anthranilic acid derivatives 1 which is superior to prior art methods such as that described l in Japanese patent application No. 8858/81.
J It is another object of this invention to provide an improved method for producing nuclear di-substituted cinnamoyl-! anthranilic acid derivatives with a high purity and yield, li which derivatives possess antiallergic properties and thus ¦¦ are useful for treatment of asthma, hay fever, atopic dermatitis i and urticaria.
! Other objects and advantages of this invention willbecome apparent from the accompanying description and examples.
i' 1241016 "
i. .' DESCRIPTION OF THE INVENTION
This invention provides an improved method for the production of nuclear substituted cinnamoylanthranilic acid ' derivatives corresponding to the formula:
i COOH
1 2~CH=CHCONH ~ (I) Ii ' jj where Rl is hydroxyl and R2 is an alkoxyl substituent containing .
j about 1-3 carbon atoms. The said derivatives possess ,1 antiallergic properties, and are useful for treatment of ! diseases caused by allergies, such as asthma, hay fever, I atopic dermatitis and urticaria.
Thus, one or more objects of the present invention are accomplished by the provision of a process which comprises i reacting a nuclear di-substituted benzaldehyde corresponding to the formula:
1, ?l i ? ~ CHO
1I Rl ~ (II) .j ll ~24~0~6 where Rl and R2 are substituents as previously defined, in ~¦ an inert organic solvent with 2-carboxymalonanilic acid corresponding to the formula:
il'' .
i 11 ~ NHCOCH2COOH (III) I.j ~ COOH
~I !
~ and a cyclic amine corresponding to the formula:
(CH2)2 ~
HN X (IV) (CH2)n ~
.1 .
Il where X is a methylene group or an oxygen atom, n is 1 or 2 ¦¦ with the proviso that n is 2 when X is an oxygen atom, and s~id l cyclic amine is employed in a molar ratio of about 2-10 moles ¦ per mole of nuclear substituted benzaldehyde derivative of l formul.(II) or the 2-carboxymalonanilic acid of Formula(III) Il Il .
I I _ 5 I ~24~
I
i! above, to produce a crystalline precipitate of an intermediate ¦¦ compound corresponding to the formula:
. . ,i ' 1,, .
I ' COO~
Rl =0_ CH=C HCoN H ~3 '¦ ~ (CH2) i H (CH2) ~
I! where Rl, R2, X and n are as previously defined; and treating '¦ the said compound ~V) under acidic conditions to yield a jl product corresponding to formula(I) above.
-In the present invention process a specific type of cyclic amine compound is utilized in a molar ratio of j 2-10 moles per mole of the starting material of formula(II) ¦ or (III).above. 8y employing a molar excess of the cyclic ¦~ amine over the benzaldehyde(II) or 2-carboxymalonanilic acid~III) compounds in an inert organic solvent as a reaction medium, the 1~ .
Il i2~1016 intèrmediate of formula(V), i.e., the salt of nuclear substituted ! cinnamoylanthranilic acid derivative and cyclic amine, precipitates as crystals in high yield and purity from the ~ reaction mixture as the reaction proceeds, and thereafter is ~ readily recovered from the reaction mixture. The crystalline compound(V) is substantially free of unreacted materials and 'j byproducts and can be converted easily into the desired l~ free acid product in a high purity form by treatment with an ~ll acidic reagent such as a mineral acid.
ll As demonstrated in the Examples, the optimal yield i! of high purity crystalline salt intermediate is achieved when l! the molar ratio of cyclic amlne to benzaldehyde(II) or i 2-carboxymalonanilic acid~III) is about 3~
l ~hus, by the practice of the present invention process ~ the problems associated with the procedure disclosed in ¦ Japanese patent application No. 8858/81 are eliminated, and il nuclear substituted cinnamoylanthranilic acid derivatives ¦ are prepared efficiently in high yield and purity.
~1 Illustrative of inert organic solvents suitable in 0 il the invention process (i.e., solvents with solubility properties which promote crystallization of the intermediate(V) Ij as the reaction proceeds) are benzehe, toluene, xylene, ethyl ¦¦ acetate and chloroform. Preferred inert organic solvents are il aromatic hydrocarbons such as benzene and toluene. The solvent 5 ~1 is employed in a volume which typically will vary between about 1-30 milliliters per gram of benzaldehyde and 2-carboxymalonanilic acid reactants.
I
1! - 7 241~
The cyclic amine component employed in the invention '~ process possesses a catalytic property for condensing a ¦¦ nuclear di-substituted benzaldehyde derivative and Il 2-carboxymalonanilic acid, and possesses properties which 1~ enhance the formation of insoluble cyclic amine salt of ,¦ cinnamoylanthranilic acid derivativë in an inert solvent ,j medium. Illustrative of the invention cyclic amines are pyrrolidine, piperidine and morpholine. Piperidine is an ¦ exceptional cyclic amine for purposes of the present invention lo 31 process.
!l Acid reagents suitable for the conversion of the ! intermediate(V) compound above into the desired compound(I) Ij include inorganic acids such as hydrochloric acid, sulfuric ! I acid, and the like, and organic acids such as acetic acid or ! p-toluenesulfonic acid. The use of a mineral acid such as ¦¦ hydrochloric acid is preferred.
The nuclear di-substituted benzaldehyde derivatives corresponding to formula(II) which are employed as a starting I¦ material are known compounds, and methods of synthesis are 1I described in the chemical literature. Examples of said aldehydes include 2-hydroxy-3-methoxybenzaldehyde; 3-hydroxy-2-methoxy-benzaldehyde; 3-hydroxy-4-methoxybenzaldehyde;4-hydroxy-3-methoxybenzaldehyde; 3-hydroxy-4-propoxybenzaldehyde:
l 4-hydroxy-3-propoxybenzaldehyde; and the like.
25 ¦ 2-Carboxymalonanilic acid used as a starting material is also a known compound, and can be prepared according to the method described in ~apanese application No. 43673/74.
l - 8 -il. . .
i~
Z410~6 ¦¦ . Since dehydration and decarboxylation reactions occur simultaneously with the formation of the intermediate compound corresponding to formula(V) above, in a preferred Il process embodiment the reaction is conducted with continuous ,I removal of water formed during the reaction course.
As a general procedure, a mixture of a benzaldehyde !! derivative corresponding to formula(II), 2-carboxymalonanilic , acid, and 2-10 moles of cyclic amine corresponding to formula(IV) l (e.g., piperidine) per mole of the benzaldehyde derivative(II) l or 2-carboxymalonanilic acid(III) is dissolved in an inert organic solvent (e.g., benzene or toluene) in a proportion l of about 1-3 liters of solvent per mole of benzaldehyde ¦¦ derivative, and then the resultant reaction solution is ¦¦ heated under reflux for a period of about 3-5 hours with 15 1l continuous removal of water as it is formed during the reaction.
ij After cooling, the precipitated crystalline salt ~! intermediate is recovered by filtration and dissolved with Il heating in water. The resultant aqueous solution is added , dropwise to a dilute mineral acid solution. The crystalline ¦¦ product which precipitates is collected by conventional means !¦ such as filtration, and optionally, recrystallized from an Il organic solvent to provide the desired product corresponding to formula(I~.
1l1 .''1 I! 9 `I ~24~016 ¦ . It is an advantage of the invention process that the cyclic amine that is utilized can be recovered from the filtrate i and recycled in the process.
Il The following Examples are further illustrative of the !¦ present invention. The specific ingredients and processing I parameters are presented as being typical, and various " modifications can be derived in view of the foregoing disclosure j' within the scope of the invention.
.
,' .
. I
,`' 1,~
I I .
i `I ~Z~0~6 'i I, EXAMPLE I
This Example illustrates the advantages of preparing j nuclear substituted cinnamoylanthranilic acid derivatives ¦j with a molar excess of cyclic amine in accordance with the ~¦ present invention process.
A.
" A solution of 2.54 g of 4-hydroxy-3-methoxy-benzaldel~yde 3.8 g of 2-carboxymalonanilic acid, and I¦ 4.29 g of piperidine in 17 ml of benzene is heated for il 3 hours under reflux with removal of water of reaction. After ¦¦ completion of the reaction, the reaction mixture is cooled and the precipitated cry,stals are collected by filtration and ¦ dried to obtain 6.34 g of piperidinium N-(4-hydroxy-3-ll methoxycinnamoyl)anthranilate, m.p. 188-189C.
5 ¦ The compound structure is confirmed by elemental analysis, and by IR and NMR spectroscopy.
Il The molar ratio of'piperidine to 4 hydroxy-3-j, methoxybenzaldehyde in the above preparation is 3:1. The ~! same procedure is employed with 3-hydroxy-4-methoxybenzaldehyde !I to synthesize piperidinium N-(3-hydroxy-4-methoxycinnamoyl)-,1 anthranilate, m.p. 197-203C.
I; The same procedure is employed with different molar il ratios of piperidine to 4-hydroxy-3-methoxybenzaldehyde and ¦l 3-hydroxy-4-methoxybenzaldehyde, respectively.
'I
1' .4~1 0~6 ' The r~sults as summarized in Table I demonstrate the superiority of the present invention process for the production of a high yield of crystalline nuclear substituted Il cinnamoylanthranilate salt intermediate. Examples II and IV
'l illustrate the conversion of the crystalline piperidinium salts to the desired N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid and N-(3-hydroxy-4-methoxycinnamoyl)anthranilic acid products.
, I .
I~ B.
il In a manner similar to that described in IA above, ¦¦ comparative runs (Table II) are conducted with different molar ¦¦ ratios of morpholine to 4-hydroxy-3-methoxybenzaldehyde and ! 3-hydroxy-4-methoxybenzaldehyde, respectively. The crystalline salt intermediates are morpholinium N-(4-hydroxy-3-methoxy-l cinnamoyl)anthranilate (m.p. 183-185C) and morpholinium i N-(3-hydroxy-4-methoxycinnamoyl)anthranilate (m.p. 133-137C, 1I with decomposition).
Il Examples III and V illustrate the conversion of the I¦ crystalline morpholinium salts to N-(4-hydroxy-3-methoxy-¦¦ cinnamoyl)anthranilic acid and N-(3-hydroxy-4-methoxy-I cinnamoyl)anthranilic acid products of the invention. I
I
, 11 , !l 1~ , Il . .
j - 12 -li ~z~o~ ;
! .
.1 .. ` c.
; In a manner similar to that described in IA above, comparative runs (Table III) are conducted with different molar l¦ ratios of pyrrolidine to 4-hydroxy-3-metho~ybenzaldehyde and ll 3-hydroxy-4-methoxybenzaldehyde, respectively. The crystalline salt intermediates are pyrrolidinium N-(4-hydroxy-3-methoxy-cinnamoyl)anthranilate (m.p. 181-186C) and pyrrolidinium N-(3-hydroxy-4-methoxycinnamoyl)anthranilate (m.p. 175-179C).
~ Examples III and V illustrate the conversion of the ¦! crystalline pyrrolidinium salts to the free acid products of i¦ the invention.
i Similar results are obtained if the benzaldehyde reactant in all of the above described procedures i8 l 3-hydroxy-2-methoxybenzaldehyde or 2-hydroxy-3-methoxy-¦ benzaldehyde.
i jl :
~I .
1. , il `.
, i', ., ~
124101~, il __ ~ ~ ~
i j ~ N ~ , ~ ~)i OG ~r ~ N ~ ~
Q' ~ Ci ~ p~ O N; ~ ~ ~r ' ~D 'i U`i 1-- 11~ N If7 N
~: O ~ "
N o ~ U ~ D .
¦ ¦v ~ s ~ G
,, ~ ~ O O )fi ~ ~ ~
~i ~ ) Qt, ~ ~ ~
i x ~ ~ ~ oo o ~ N
~~ ~ u~
~ ~ V V . .. , il . ,~ ~, ~., ~_ ~ ~_ ~_ 9j~ , ~ Gi O N 1~ O
¢ ~ ~ ~i ~ OCi ~ N ~ t~ i 1` O 11~ ll~i 1~
~ ! Qi ~ O i~ S~ O ~ ~ ci N ~D O 11~ N
¦ ~i 0 Lo' ~C N ~
~ N O ~ ~ ~,~i ~ ~
lll ~ )=\ Ci ~ ~ ., ...... .. ~P d~ dP ~P oP dP ;
,i ,~x ~ ~ ~ ~ i t` Ni, I`
i l ~ ~i s~? ~
~ l x~ ~ ~ ~ ~
~i ~ ~i ?i ~ ~ a~ r, ~i No I' . ~ . "~
` !
~'i / Q' C / E ~ o o o o o ., / ~'i ,, / ~ C~
?? / z , i /
? _ `lZ41~
ll a) ~ ~ ~ ~ _.
~ ~ Ul ~ ~ O~ O ~D o O N ~ ~ ~ ~ a~ ~
., ~ ~ ~ O h Q~ O ~D ~ o ~ ~ ~ N
;~ ' 1~1 ~1 ~ O
,1 . ~ O O ~ Q, ~
. 3 X P: ~ ~ ~3 .
~i l ~ O
.,1 ~ ~
' 'I ~ ----- ., a ~1 ~ ~ O~ r oo o~ o I ¦ H ~ ~ 0~ ,_~ ~ ~1 er CO 1`
I I ~ ~ O ~ ~ ~ =~ O 0 ~
! l X /~\ ~g V ~ d~ dP dP dP d~ dP ;
, . E 0~/ V ~ ~ ~ ~ ~
. ~ h O 3 ~
ll ~ ~o~ ~ ~ ~
s . ~ ~ ~ ~
, I er ~ .~ h ~ ~r u7 a~ o j~
1~ . ~ In.
ll ... ''/ ._ _ _ __ _ l i.1 ~ / ~ ~ o o o o o .I j ~ / o ll / _ . __ __ k ~ ~ _ .- I
~. . I
__ ~ 016 .
I ~ ~ o ~ In o ~ J~ U) ~ ~i ~
!' ~ ~ o ~ ~ z~
. ~ . ~1 O ~ ~1 i! ~ ~ o~
! 1. o , I ~ ~ ~ 1~ h ~ 3oo ~, O O ~ X ~.
X ~ ~ o O ~ .~ ~ ~ ~
~o~-~ ~ ~ ~ ~ ~ O
j ~ ~ ~ o 'I ~ ~ . ~
;j ! I __ . I , ~, X~
! ~ ~ ~
~ . a) 3 ~ o ~ o ~D
I ~ It b~ 5 ,~ trt ~t o H ~ ~ O ~1 ~ _~ ~ cn a~ 1` 1`
i H 0~ ,~
i ~1 N ~ ~1 ~r ~ N
, m ~ 5: ~ ~ u ,~, ~D
Il ~ ~ U ~ ~t 9~ ~g i j Q ~ ~0 ~ -~ .. .. .. dP d d~ d~ dP ~P ? `
X ~ ~1 ut ~ t ~ ~ ~ u 1 ~ ~ ~.~2 ~ ~
~ ~ ~ ~ Qtl ' ~ o b' ~ ~
,~ s~ ~n ~ ~ ~ ~ ~' 1 ~ ~o~ ~ ~
I ! ~ rl ut r~
1 ~ ~2 u~
~l /
i ~ / a) ! ~ ~ ~ ~ o o o o o ~
; ~ /
! / ~ ~) Il / ~:
/
, C
I1 ~24~016 j' ~ EXAMPLE II
',l A 10 g quantity of piperidinium N-l4-hydroxy-3-methoxy-cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of Il water and 60 ml of methyl alcohol with heating, and the ~I resultant solution is added dropwise to 85 ml of diluted ~, hydrochloric acid (5 ml of conc. hydrochloric acid and ~0 ml of water) with stirring. The precipitated crystals which form are collected by filtration, washed with water and then dried at ,j 90-100C under r~duced pressure for 3 hours to yield ¦I N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid (98.5% yield), ¦i m.p. 230-233C. The compound structure is confirmed by jl elemental analysis, and by IR and NMR spectroscopy.
~1 , EXAMPLE III
~ A 10 g quantity of morpholinium N-(4-hydroxy-3-methoxy-I cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of ! water and 60 ml of methyl alcohol with heating, and the "
resultant solution is added dropwise to 85 ml of diluted hydrochloric acid t5 ml of conc. hydrochloric acid and 80 ml of ~, water) with stirring. The precipitated crystals which form are i~ collected by filtration, washed with water and then dried at 'i 90-100C under reduced pressure for 3 hours to yield Ij N-(4-hydroxy-3-methoxycinnamoyl)anthranilic acid (82.5~ yield).
il The compound is confirmed as identical to that obtained in I, EXAMPLE II.
!~ Similar results are obtained with pyrrolidinium ~j N-(4-hydroxy-3-methoxycinnamoyl)anthranilate.
!
I' . .
, - 14 -jl 124101~
. XAMPLE IV
A 10 g 4uantity of piperidlnium N-(3-hydroxy-4-methoxy-! cinnamoyl)anthranilate is dissolved in a mixture of 80 ml of l water and 80 ml of methyl alcohol with heating, and the resultant ~jgolution is added dropwise to 85 ml of diluted hydrochloric acid ,l(5 ml of conc. hydrochloric acid and 80 ml of water) with ~ stirring. The precipitated crystals which form are collected ,',by filtration, washed with water and then dried at 90-100C
,lunder reduced pressure for 3 hours to yield N-(3-hydroxy-4-I¦methoxycinnamoyl)anthranilic acid (97.0% yield), m.p. 219-222C.
¦I The compound structure is confirmed by elemental analysis, and ¦~ by IR and NMR spectroscopy.
11 , I ~ EXAMPLE V
' A 10 g quantity of morpholinium N-(3-hydroxy-4-methoxy-l cinnamoy)anthranilate is dissolved in a mixture of 80 ml of ~ water and 60 ml of methyl alcohol with heating, and the resultant ;
jj solution is added dropwise to 85 ml of diluted hydrochloric acid j (5 mlof conc. hydrochloric acid and 80 ml of water) with stirring-, j~ The precipitated crystals which form are collected by filtration, 'I washed with water and then dried at 90-100C under reduced pressure for 3 hours to yield N-t3-hydroxy-4-methoxycinnamoyl)-,l anthranilic acid (74.0% yield). The compound is confirmed as identical to that obtained in EX~IPLE IV.
I¦ Similar results are obtained with pyrrolidinium 1¦ N- (3-hydroxy-4-metlloxycinnamoyl) anthr\nilate.
Il - 15-il .
Claims (11)
1. A process for the production of a nuclear substituted cinnamoylanthranilic acid derivative corresponding to the formula:
where R1 is hydroxy and R2 is an alkoxyl group containing about 1-3 carbon atoms, which process comprises (1) reacting in an inert organic solvent medium a nuclear substituted benzaldehyde derivative corresponding to the formula:
where R1 and R2 are as previously defined, with 2-carboxy-malonanilic acid and a cyclic amine corresponding to the formula:
where X is a methylene group or an oxygen atom, n is 1 or 2 with the proviso that n is 2 when X is an oxygen atom, and said cyclic amine is employed in a molar ratio of about 2-10 moles per mole of substituted benzaldehyde derivative reactant or 2-carboxymalonanilic acid reactant, to produce a crystalline precipitate of an intermediate compound corresponding to the formula:
where R1, R2, n and X are as previously defined; and (2) treating the intermediate compound with an acidic reagent to yield a nuclear substituted cinnamoylanthranilic acid product corresponding to the first formula above.
where R1 is hydroxy and R2 is an alkoxyl group containing about 1-3 carbon atoms, which process comprises (1) reacting in an inert organic solvent medium a nuclear substituted benzaldehyde derivative corresponding to the formula:
where R1 and R2 are as previously defined, with 2-carboxy-malonanilic acid and a cyclic amine corresponding to the formula:
where X is a methylene group or an oxygen atom, n is 1 or 2 with the proviso that n is 2 when X is an oxygen atom, and said cyclic amine is employed in a molar ratio of about 2-10 moles per mole of substituted benzaldehyde derivative reactant or 2-carboxymalonanilic acid reactant, to produce a crystalline precipitate of an intermediate compound corresponding to the formula:
where R1, R2, n and X are as previously defined; and (2) treating the intermediate compound with an acidic reagent to yield a nuclear substituted cinnamoylanthranilic acid product corresponding to the first formula above.
2. A process in accordance with claim 1 wherein the mixture of reagents in step (1) is heated under reflux with continuous removal of water as it is formed during the reaction.
3. A process in accordance with claim 1 wherein the inert organic solvent is an aromatic hydrocarbon.
4. A process in accordance with claim 1 wherein the inert organic solvent is benzene or toluene.
5. A process in accordance with claim 1 wherein the benzaldehyde reactant is 4-hydroxy-3-methoxybenzaldehyde.
6. A process in accordance with claim 1 wherein the benzaldehyde reactant is 3-hydroxy-4-methoxybenzaldehyde.
7. A process in accordance with claim 1 wherein the cyclic amine is piperidine.
8. A process in accordance with claim 1 wherein the cyclic amine is morpholine.
9. A process in accordance with claim 1 wherein the cyclic amine is pyrrolidine.
10. A process in accordance with claim 1 wherein said nuclear substituted benzaldehyde derivative is 4-hydroxy-3-methoxybenzaldehyde and the resulting nuclear substituted cinnamoylanthranilic acid product is N-(4-hydroxy-3-methoxy-cinnamoyl)anthranilic acid.
11. A process in accordance with claim 1 wherein said nuclear substituted benzaldehyde derivative is 3-hydroxy-4-methoxybenzaldehyde and the resulting nuclear substituted cinnamoylanthranilic acid product is N-(3-hydroxy-4-methoxy-cinnamoyl)anthranilic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/654,231 US4587356A (en) | 1981-09-01 | 1984-09-25 | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives |
US654,231 | 1984-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1241016A true CA1241016A (en) | 1988-08-23 |
Family
ID=24624008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000478780A Expired CA1241016A (en) | 1984-09-25 | 1985-04-10 | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1241016A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144933A1 (en) * | 2007-05-29 | 2008-12-04 | Université de Montréal | Cinnamoyl inhibitors of transglutaminase |
-
1985
- 1985-04-10 CA CA000478780A patent/CA1241016A/en not_active Expired
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144933A1 (en) * | 2007-05-29 | 2008-12-04 | Université de Montréal | Cinnamoyl inhibitors of transglutaminase |
US8614233B2 (en) | 2007-05-29 | 2013-12-24 | Universite De Montreal | Cinnamoyl inhibitors of transglutaminase |
US9162991B2 (en) | 2007-05-29 | 2015-10-20 | University Of Ottawa | Cinnamoyl inhibitors of transglutaminase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4486597A (en) | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | |
US4587356A (en) | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives | |
US5239077A (en) | Highly pure amidoximes | |
CA1241016A (en) | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | |
Jagdmann Jr et al. | A mild efficient procedure for the conversion of carboxylic acid esters to primary amides using formamide/methanolic sodium methoxide | |
US4665197A (en) | Process for preparing azetidine derivatives and intermediates thereof | |
JPH05509319A (en) | Method for producing substituted pyridines via 1-aza-1,3-butadiene and 1-aza-1,3-butadiene intermediate | |
JPH0782268A (en) | Production of benzothiadiazole derivative | |
JPH0458468B2 (en) | ||
JP2782698B2 (en) | Novel method for producing 9-amino-1,2,3,4-tetrahydroacridine | |
CA1050988A (en) | Process for preparation of benzoylpyridines and derivatives | |
US3019227A (en) | Alkyl acridines | |
Burger et al. | Amino Derivatives of 2, 2-Diphenylcyclohexanone. I1 | |
KR880000763B1 (en) | Method for preparing nuclear substituted cinnamoyl amino anthranilic acid derivatives | |
CA2040110A1 (en) | Process for preparing pyridine and quinoline derivatives | |
JP3563424B2 (en) | Method for producing 4H-pyran-4-one | |
SU959622A3 (en) | Process for producing derivatives of benzocycloheptene or their salts | |
Papadopoulos et al. | Reactions of lucigenin in protic solvents in the presence of amines | |
JPS6119624B2 (en) | ||
SU507567A1 (en) | Method for producing substituted dithiocarbamates | |
CH620414A5 (en) | ||
JP2767295B2 (en) | Method for producing indole-3-carbonitrile compound | |
US3347864A (en) | Production of aminoquinolines | |
JP4287083B2 (en) | Process for producing 2- or 4-monosubstituted pyridine and process for selective production and separation of 4-monosubstituted pyridine or a salt thereof | |
CN113121418A (en) | Preparation method of 1, 4-dihydropyridine-3, 5-dimethylamide compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |